The EIF4G3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma line, engineered to disrupt the EIF4G3 gene. This loss-of-function model eliminates functional EIF4G3 protein expression, providing a well-defined system to interrogate the molecular dependencies of cap-dependent translation initiation. The polyclonal nature retains heterogeneity seen in bulk-edited populations, suitable for functional genomics and pooled screening applications without the selective pressure of clonal isolation. As a targeted gene disruption product, it allows researchers to dissect the specific contribution of EIF4G3 within the translation machinery across diverse cellular contexts.
The HeLa host cell line is an HPV18-positive epithelial cell model derived from a human cervical adenocarcinoma, widely employed in cancer biology, signal transduction, and drug response studies due to its robust growth and well-characterized signaling networks. The epithelial origin and transformed phenotype make HeLa cells particularly relevant for exploring mechanisms of oncogenic translation and proliferative control. The integration of the EIF4G3 knockout into this established background provides a tractable platform to examine how loss of a key translation scaffold factor impacts cellular fitness, drug sensitivity, and global protein synthesis in a cancer-relevant setting.
EIF4G3 serves as a scaffold protein within the eIF4F translation initiation complex, bridging the mRNA 5?? cap via eIF4E and the 3?? poly-A tail via PABPC1, while simultaneously recruiting the 40S ribosomal subunit through eIF3 to drive cap-dependent translation. Knockout of EIF4G3 disrupts this assembly, impairing the efficient translation of mRNAs with structured 5?? UTRs, including key oncogenic transcripts such as MYC, CCND1, BCL2, and VEGF. EIF4G3 is regulated upstream by mTORC1 and growth factor receptors (EGFR, IGF1R) via the MAPK/ERK pathway, leading to MNK-mediated eIF4E phosphorylation. Interacting factors include eIF4E, eIF4A, PABPC1, eIF4B, the eIF3 complex, and MNK1/2 kinases, establishing EIF4G3 as a critical node for integrating mitogenic and stress signals to control translation output.
In the HeLa cervical adenocarcinoma context, where both mTOR and MAPK/ERK pathways are frequently hyperactive, EIF4G3 knockout likely attenuates the translation of proliferation- and survival-promoting proteins, offering a unique tool to study the translation-dependent mechanisms that sustain malignant growth. This model is particularly suited to investigate how cancer cells adapt to the loss of cap-dependent initiation, potentially engaging alternative translation modes such as IRES-driven translation. Moreover, it provides a physiologically relevant system to explore synthetic lethal interactions and to screen for compounds that exhibit enhanced cytotoxicity when translation initiation is compromised, informing potential therapeutic strategies against mTOR- or eIF4F-addicted tumors.
Researchers can employ this polyclonal knockout population in a variety of assays, including Western blotting to verify target loss and downstream effector expression, polysome profiling to assess global and mRNA-specific translation shifts, cap-binding assays to measure eIF4F complex integrity, and cell proliferation or migration assays to evaluate functional consequences. RNA-seq and quantitative proteomics further enable systems-level analyses of translational control. Drug sensitivity testing against mTOR inhibitors, MNK inhibitors, or standard chemotherapeutics can reveal resistance mechanisms mediated through EIF4G3-dependent protein synthesis. For additional technical details and ordering information, please contact Ascent Research.
